Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome - Centre de recherche des Cordeliers Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2018

Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome

Résumé

Co-stimulatory and inhibitory receptors expressed by immune cells in the tumor microenvironment modulate the immune response and cancer progression. Their expression and regulation are still not fully characterized and a better understanding of these mechanisms is needed to improve current immunotherapies. Our previous work has identified a novel ligand/receptor pair, LLT1/CD161, that modulates immune responses. Here, we extensively characterize its expression in non-small cell lung cancer (NSCLC). We show that LLT1 expression is restricted to germinal center (GC) B cells within tertiary lymphoid structures (TLS), representing a new hallmark of the presence of active TLS in the tumor microenvironment. CD161-expressing immune cells are found at the vicinity of these structures, with a global enrichment of NSCLC tumors in CD161+ CD4+ and CD8+ T cells as compared to normal distant lung and peripheral blood. CD161+ CD4+ T cells are more activated and produce Th1-cytokines at a higher frequency than their matched CD161-negative counterparts. Interestingly, CD161+ CD4+ T cells highly express OX40 co-stimulatory receptor, less frequently 4-1BB, and display an activated but not completely exhausted PD-1-positive Tim-3-negative phenotype. Finally, a meta-analysis revealed a positive association of CLEC2D (coding for LLT1) and KLRB1 (coding for CD161) gene expression with favorable outcome in NSCLC, independently of the size of T and B cell infiltrates. These data are consistent with a positive impact of LLT1/CD161 on NSCLC patient survival, and make CD161-expressing CD4+ T cells ideal candidates for efficient anti-tumor recall responses.
Fichier principal
Vignette du fichier
Braud-Oncoimmunol-18-reduit.pdf (1.46 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-02265250 , version 1 (06-11-2020)

Identifiants

Citer

Veronique Braud, Jérôme Biton, Etienne Becht, Samantha Knockaert, Audrey Mansuet-Lupo, et al.. Expression of LLT1 and its receptor CD161 in lung cancer is associated with better clinical outcome. OncoImmunology, 2018, 7 (5), pp.e1423184. ⟨10.1080/2162402X.2017.1423184⟩. ⟨hal-02265250⟩
115 Consultations
11 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More